Following on from information provided to NICE by the company in April 2021, the appraisal of Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.